Legis Daily

Triple-Negative Breast Cancer Research and Education Act of 2021

USA117th CongressHR-113| House 
| Updated: 2/2/2021
Sheila Jackson Lee

Sheila Jackson Lee

Democratic Representative

Texas

Cosponsors (1)
Frederica S. Wilson (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Triple-Negative Breast Cancer Research and Education Act of 2021 This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors. Specifically, the National Institutes of Health must conduct and support research into the disease. Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-5939
Triple-Negative Breast Cancer Research and Education Act of 2019
Jan 4, 2021
Introduced in House
Jan 4, 2021
Referred to the House Committee on Energy and Commerce.
Feb 2, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-5939
    Triple-Negative Breast Cancer Research and Education Act of 2019


  • January 4, 2021
    Introduced in House


  • January 4, 2021
    Referred to the House Committee on Energy and Commerce.


  • February 2, 2021
    Referred to the Subcommittee on Health.

Health

CancerGovernment information and archivesHealth information and medical recordsHealth programs administration and fundingHealth promotion and preventive careMedical educationMedical researchMinority healthResearch administration and fundingWomen's health

Triple-Negative Breast Cancer Research and Education Act of 2021

USA117th CongressHR-113| House 
| Updated: 2/2/2021
Triple-Negative Breast Cancer Research and Education Act of 2021 This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors. Specifically, the National Institutes of Health must conduct and support research into the disease. Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-5939
Triple-Negative Breast Cancer Research and Education Act of 2019
Jan 4, 2021
Introduced in House
Jan 4, 2021
Referred to the House Committee on Energy and Commerce.
Feb 2, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-5939
    Triple-Negative Breast Cancer Research and Education Act of 2019


  • January 4, 2021
    Introduced in House


  • January 4, 2021
    Referred to the House Committee on Energy and Commerce.


  • February 2, 2021
    Referred to the Subcommittee on Health.
Sheila Jackson Lee

Sheila Jackson Lee

Democratic Representative

Texas

Cosponsors (1)
Frederica S. Wilson (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
CancerGovernment information and archivesHealth information and medical recordsHealth programs administration and fundingHealth promotion and preventive careMedical educationMedical researchMinority healthResearch administration and fundingWomen's health